ValiRx plc (GB:VAL) has released an update.
ValiRx Plc’s subsidiary Inaphaea BioLabs has entered into a co-marketing agreement with U.S. firm Spanios LLC to enhance drug screening and development services. The collaboration combines Inaphaea’s high throughput drug screening using Patient Derived Cells with Spanios’s Patient Derived Tumoroids platform, aiming to accelerate the drug development process. The initial agreement spans 12 months, with possibilities for extension, marking Inaphaea’s first co-marketing move in the U.S.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
